Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 10/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260956 | 0.93 | CFD (0.44) | CFDADORA2AADORA1ALDH1A1KDM4E | |
| SCHEMBL5263193 | 0.84 | KDM4E (0.48) | CFDALDH1A1KDM4EHSD17B10POLB | |
| SCHEMBL5262020 | 0.84 | LMNA (0.39) | CFDALDH1A1KDM4EPOLBHTT | |
| SCHEMBL5264473 | 0.83 | MAPT (0.44) | ALDH1A1KDM4EHSD17B10POLBHTT | |
| SCHEMBL5260416 | 0.83 | KDM4E (0.40) | CFDALDH1A1KDM4EHSD17B10POLB | |
| SCHEMBL5259657 | 0.79 | AKR1C3 (0.41) | ALDH1A1KDM4EHSD17B10HTTCNR2 | |
| SCHEMBL5260904 | 0.77 | HTR1A (0.39) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL5264178 | 0.77 | KDM4E (0.50) | CFDALDH1A1KDM4EHSD17B10POLB | |
| SCHEMBL5266123 | 0.76 | MEN1 (0.50) | SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL5260022 | 0.76 | MAPT (0.45) | ALDH1A1KDM4EHSD17B10POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | claimed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | CFD 4453/4885ADORA2A 65/4885ADORA1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.